|
The
Hunt for a Known Cure
Scientists Embark Upon Hunt To Find Iron-Controlling
Molecule That Will Quell Colon/Rectal Cancer; But the Molecule Already
Exists
by
Bill Sardi
Recently
by Bill Sardi: Marching
to Dementia
One of the
dirty little secrets of modern medicine, and a reason why healthcare
costs are so high, is that researchers and clinicians are trying
to profiteer by inventing and delivering the highest cost medicine.
Ten-cent cures are not to be found. Patentable, costly man-made
medicines reign. Natural medicines are shunned or ignored.
Such is the
case where British scientists claim they have discovered high iron
levels in the colon/rectum raise the risk for cancer and say they
are avidly searching for chelating (key-lay-ting) molecules that
will mop up the iron and reduce the risk or even treat active colon/rectal
cancer. They
say they hope to start using these molecules in the coming years.
But high-risk individuals with polyps in their colon or who have
a history of bowel inflammation can reach for a cure that is already
at hand.
A molecular
cure already exists and is found in nature. It is the reason why
whole-grain
and high-fiber
diets reduce the risk for colon/rectal cancer. A master iron-chelating
molecule called IP6 (for inositol hexa-phosphate), found in the
bran portion of grains and seeds, which is an available dietary
supplement as a purified rice bran extract, has been demonstrated
to inhibit colon/rectal cancer in numerous studies and inactivates
the very same cancer-promoting gene (Wnt) shown in the newly
published study in Britain. In one study IP6
decreased the uptake of iron in cells found in the colon by 50-65%.
This landmark
study, published in journal Cell
Reports, is stunning. While high-iron diets (particularly highly-absorbable
iron from red meat) have consistently been shown to increase
the risk for colon cancer, iron
blood levels are not consistently correlated with this malignancy.
Researchers show all the damaging effects of iron are local – in
the colon and rectum.
The striking
discovery is that even a high-iron diet will not induce tumors in
these digestive tract tissues as long as a tumor-suppressing gene
called Apc is functional. But researchers note that uncontrolled
iron appears to increase mutation rates in the Apc gene that in
turn inactivates its cancer-inhibiting action. Then two iron-accumulating
genes (transferrin receptor 1 and divalent metal transporter 1)
are switched on and iron pools in these tissues that results in
the activation of a tumor-promoting gene (Wnt).
Researchers
say: "chelation of this pool of iron may provide a platform
for therapeutic intervention." A class
of chelators that inhibits the Wnt cancer-promoting gene has been
identified.
But while there
are expensive and problematic iron-chelating drugs, the safest and
most economical is IP6. In 2001 researchers at the Food & Drug
Administration declared IP6
to be one of only four non-mutagenic iron-chelating molecules.
It would be the first truly preventive cancer therapy as no preventive
measures are currently practiced beyond early detection.
Expensive iron
chelators, most which require intravenous administration, are not
appropriate for high-risk individuals who do not have active forms
of colon/rectal cancer. However, IP6 does butt heads with the Food
& Drug Administration’s requirement that a dietary supplement
cannot cure, treat or prevent any disease without being declared
a drug.
But all high-risk
patients need do is head for a local health food store, they don’t
need permission from the FDA. A
30-day supply of two IP6 capsules sells for around $10 compared
to the prescription oral chelator deferasirox
that sells as a generic drug for around for $599.00/30 -500 mg tablets.
For comparison the annual cost of generic deferasirox would be ~$7188/year
compared to a 2-capsules per day regimen of IP6 around $60/year.
Intravenous chelators cost thousands of dollars per year.
A long list
of side
effects are associated with deferasirox. These include but are
not limited to: stomach pain, nausea, vomiting and diarrhea. Some
side effects can be serious, such as: hearing loss, vision problems,
hives, rash, blisters, itching, difficulty breathing or swallowing,
swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles,
or lower legs, hoarseness
It’s estimated
that 30 to 50 percent of Americans over 50 have or will develop
adenomas, but only between 1 and 10 percent of these polyps will
progress to cancer in 5 to 10 years. So it would be overtreatment
to prescribe expensive and problematic oral chelators for everyone
who has diagnosed intestinal polyps.
A link between
excess iron and colon cancer incidence has been repeatedly reported.
Among 33studies, 75%
of them support an association between excess iron and colon cancer
risk.
The rationale
to reduce the iron load is strong. Researchers already know that
depletion
of stored iron via blood donation or blood-letting decreases
the risk for various cancers including colon cancer.
Researchers
have been calling
for human studies of IP6 since 2003. Another report about IP6
and cancer by this author was published in 2005.
A striking
fact within this study is that patients at high-risk for colon cancer,
those with polyps in their colon and rectum or who have inflammatory
bowel disease, are often anemic due to binding of iron from chronic
inflammation. The current practice among these anemic patients is
to prescribe high dose oral iron tablets. The researchers in this
study say this practice "is likely to both exacerbate their
condition and elevate their risk for developing colon/rectal cancer."
(How many patients with anemia from chronic inflammatory bowel disease
have met their early demise this way? This author can recall quite
a few in his experience.) These researchers suggest supplemental
iron be given intravenously and followed by iron chelation therapy.
How many more patients will die of iron therapy before the word
gets out about this?
|
Effect
of intact or defective Apc gene and
low and high iron diets in colon cells
|
|
Apc
(adenomatous polyposis coli) Gene Is The Most Commonly Mutated
Gene In Colon/Rectal Cancer
|
Low
Iron Diet
|
High
Iron Diet
|
|
Intact
(active) Apc gene
Reduces cellular iron locally in the colon/rectum; protects
Apc gene
|
No
cancer
|
No
cancer
|
|
Defective
(mutated) Apc gene
Increases cellular iron locally in colon/rectum; switches
on Wnt tumor activator gene
|
No
cancer
|
2-3
times increased risk
|
|
Defective
Apc gene + intravenous (not local) iron chelator. Chelator
must be taken orally and come in contact with cells in the
colon and rectum
|
No
effect on tumor generation
|
No
effect on tumor generation
|
|
Source:
Luminal Iron Levels Govern Intestinal Tumorigenesis after
Apc Loss In Vivo,
Cell Reports, 09 August 2012
|
August
16, 2012
Bill
Sardi [send
him mail] is a frequent writer on health and political
topics. His health writings can be found at www.naturalhealthlibrarian.com.
His
latest book is Downsizing
Your Body.
Copyright
© 2012 Bill Sardi Word of Knowledge Agency, San Dimas, California.
This article has been written exclusively for www.LewRockwell.com
and other parties who wish to refer to it should link rather than
post at other URLs.
The
Best of Bill Sardi
|